Biophan Technologies, Inc.Company Overview

Michael Weiner, CEOCinapsys Microcap Conference

June 29, 2005

Biophan’s Mission

• Provide competitive advantage through innovation to biomedical device and pharmaceutical companies

• Benefiting patient care, our customer’s marketshare, and Biophan shareholders

CAUTION! CAUTION!

• FORWARD LOOKING STATEMENTS FOLLOW

• FORWARD LOOKING STATEMENTS FOLLOW

Strategy & Tactics

• Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not:

– Guidewires, catheters, endoscopes, biopsy needles– Pacemakers, defibrillators, neurostimulators, drug pumps

(safety issues, also imaging issues), pain control devices– Stents, embolism clips, aneurysm clips, artificial hips, knees,

most other orthopedics

• Create or Acquire Other Innovations

Business Model• Offering our customers competitive advantage

– Through proprietary solutions that can gain marketshare for them

– FDA approval is pursued by the customer– Marketing and distribution of the final device is their

responsibility

• We sell high margin components and develop annuities for our shareholders

Summary Financial Information

• Share Price (06.21.05): $2.55• 52-Week High: $3.50• 52 Week Low: $0.46• Shares Outstanding: 74 million• Float: 65 million• Market Cap: $189.5 million• Average Daily Volume: 998,672

Biophan’s Solutions

• MRI Safety: (many products contraindicated)– RF filter from Johns Hopkins (heating)– “Anti-Antenna” lead design (heating & induced voltages)– MRI Safe non-magnetic motor

• MRI Visualization: – Resonant Circuits– Nanomagnetic Particle Coatings– Thick and thin film coatings

• Longer Lasting Batteries, powered by body heat

PROTECTED, PROTECTED!

• Technologies covered by– 140 U.S. Patents

• 38 ISSUED• 102 pending or allowed

• 46 International Pending or Issued• Owned by Biophan or licensed exclusively to

Biophan for the medical market

Relationship With Boston Scientific

• Joint development agreement, originally entered into November, 2003

• Recently moved to second and third phase, and has expanded to multiple products

• Reached agreement on term sheet, working on

final contract phase

MRI Device Imaging

SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.

1 2 3

Biophan’s thin-film

nanomagnetic particle

coating technology

provides a controllable,

“magnetic” signal

capable of creating an

image of the coated

device.

#3 is uncoated.

1.5 Tesla MRI Artifacts of Current Stents

Expanded

StentsOriginal size

Crimped

Stents

Cobalt

316L stainless steel

With existing stent

technology, no useful

images can be obtained from within

common stents using

MRI.

Imaging of In-Stent Blood Clots Using Biophan Resonator Technology

1 Tesla Philips NT, head coil, TR=300ms, TE=6ms, FA=40°,

transversal

Cross Sectional Schematic of Stent with blood clot

Video

Biophan’s technology enables imaging of the blood clot within the stent

Resonant Stent

Blood Clot

Biothermal Battery

• Goal: To provide a long-lived electrical power system for implanted medical devices

– Powered by body heat differential.

• Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets

• Sold to same customers who need MRI safety

• Nanomaterials brings this capability within striking distance. We hold issued and pending patents

Agreement with NASA

• Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery

– NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices

– Biophan gets commercial rights to jointly developed and NASA developed technology

– Nanotechnology and materials science advances makes the biothermal battery possible

• Non-Magnetic• MRI-Safe and

Imageable • Greater

efficiency• Enables precision

20 nm movements

• Ideal for drug pumps, cryogenic applications, implantables

• Biophan holds worldwide medical distribution rights, + equity

Substrate

Polymer Coating

Nanomagnetic layer

Con

trol

led

Mag

netic

Fie

ldDrug bound to NMP carrier

Con

trol

led

Mag

netic

Fie

ld A

Con

trol

led

Mag

netic

Fie

ld B

Particle type ADrug AParticle type BDrug B

Surface Elution on Demand

Reloading Drug Eluting Coatings

Substrate

Polymer Coating

Concentration G

radient

Controlled

Magnetic F

ield

Drug Molecules

Drug bound to NMP carrier

Nanomagnetic layer

Guided Drug Delivery

Solid tumor

Apply magnetic field to concentrate particles

Modulate field to release drug from particles

Inject NMPs IV,NMP will circulate through the blood stream

Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor

Markets• Medical devices (safe &/or image): $12 billion• Battery: $500 million • Contrast Agents: $800 million • Drug Pumps: $1 billion• Drug Delivery: $40 billion• We would like to achieve a slice of each. • Once a deal is underway, patents and annuity streams can

last a long time; • We anticipate money on signing, through development; plus

milestones, royalties, high margin components

Management

• Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization

• Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division

• John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)

• Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms

• Michael Friebe, Ph.D.

• Andreas Melzer, MD

Biophan (OTC: BIPH)

We don’t make medical devices; We make them safe, and imageable, for MRI

And other competitive advantages for our customers

Four of our six technologies are based on nanotechnology

WWW.BIOPHAN.COM